Japanese biotech firm EdiGENE raises $14.4m in Series B

Laboratory equipment. Photo: Pixabay

EdiGENE, a Japanese biotechnology firm that develops CRISPR-based therapies, has raised ¥1.6 billion ($14.4 million) in its Series B funding round led by UTokyo Innovation Platform, the University of Tokyo’s investment arm for innovations and startups.

Continue reading this story with a subscription to DealStreetAsia.

Subscribe

Contact us for corporate subscriptions at subs@dealstreetasia.com.